Author:
Zisis Konstantinos,Athanasakis Kostas,Souliotis Kyriakos
Publisher
Springer Nature Singapore
Reference68 articles.
1. Adamski J, Godman B, Ofierska-Sujkowska G, Osińska B, Herholz H, Wendykowska K, Laius O, Jan S, Sermet C, Zara C, Kalaba M, Gustafsson R, Garuolienè K, Haycox A, Garattini S, Gustafsson LL (2010) Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Serv Res 7(10):153. https://doi.org/10.1186/1472-6963-10-153
2. Alarkawi D, Ali MS, Bliuc D et al (2018) The challenges and opportunities of pharmacoepidemiology in bone diseases. JBMR Plus 2(4):187–194
3. Allen N, Walker SR, Liberti L, Salek S (2017) Health technology assessment (HTA) case studies: factors influencing divergent HTA reimbursement recommendations in Australia, Canada, England, and Scotland. Value Heal 20(3):320–328. https://doi.org/10.1016/j.jval.2016.10.014
4. Babar Z (2019) Encyclopedia of pharmacy practice and clinical pharmacy, 1st edn. Elsevier Academic Press
5. Balçık YP, Şantaş G (2016) Pharmacoepidemiology. IOSR J Pharm 6:2250-3013